Does size matter?

FDA last week launched what it hopes will be a lively public discussion on whether extremely sensitive outcomes measures or very large trials can produce efficacy results that are statistically significant but are too clinically trivial to support approval.

At bottom is the question of whether FDA should make approvals contingent on achieving minimum levels of efficacy. Senior staff say they want the issue aired publicly, but they lean against such a requirement...